
    
      This is an open-label, single-center, randomized, single-dose, 3-treatment, 3-period,
      6-sequence crossover study in healthy adult participants consisting of approximately 7 weeks
      of treatment. The study population will be limited to extensive metabolizers of cytochrome
      P450 (CYP) 2D6.

      Approximately 18 participants will be randomly assigned to 1 of 6 sequences (ABC, ACB, BAC,
      BCA, CAB, CBA).
    
  